Table 2.
Marker Prevalence and Association With Histopathologic Variables
| Characteristic | Stage II Patients: CALGB 9581 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMR Status |
18q Status |
|||||||||||
| Patients With MMR-D Tumors |
Patients With MMR-I Tumors |
P | Patients With 18q Intact |
Patients With 18qLOH Tumors |
Patients With Noninformative 18qLOH |
P | ||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | |||
| No. of patients | 199 | 736 | 71 | 222 | 60 | |||||||
| Treatment | .76 | .54 | ||||||||||
| MoAb 17-1A | 103 | 51.8 | 372 | 50.5 | 43 | 60.6 | 118 | 53.2 | 32 | 53.3 | ||
| Observation | 96 | 48.2 | 364 | 49.5 | 28 | 39.4 | 104 | 46.8 | 28 | 46.7 | ||
| Age, years | .24 | .66 | ||||||||||
| Mean | 65 | 64 | 63 | 65 | 64 | |||||||
| Range | 30–87 | 33–90 | 36–87 | 33–89 | 38–79 | |||||||
| Sex | .002 | .37 | ||||||||||
| Male | 85 | 42.7 | 405 | 55.0 | 35 | 49.3 | 121 | 54.5 | 37 | 61.7 | ||
| Female | 114 | 57.3 | 331 | 45.0 | 36 | 50.7 | 101 | 45.5 | 23 | 38.3 | ||
| Site of tumor | < .001 | .13 | ||||||||||
| Distal | 27 | 13.6 | 339 | 46.6 | 27 | 38.0 | 114 | 51.4 | 28 | 46.7 | ||
| Proximal | 72 | 86.4 | 394 | 53.5 | 44 | 62.0 | 107 | 48.2 | 32 | 53.3 | ||
| Unknown | 0 | 3 | 0.4 | 0 | 1 | 0.4 | ||||||
| Tumor differentiation | < .001 | .40 | ||||||||||
| Well | 12 | 6.0 | 68 | 9.2 | 6 | 8.4 | 21 | 9.5 | 6 | 10.0 | ||
| Moderate | 122 | 61.3 | 584 | 79.4 | 53 | 74.6 | 175 | 78.8 | 50 | 83.3 | ||
| Poor/undifferentiated | 64 | 32.2 | 79 | 10.7 | 12 | 16.9 | 25 | 11.3 | 3 | 5.0 | ||
| Unknown | 1 | 0.5 | 5 | 0.7 | 0 | 1 | 0.4 | 1 | 1.7 | |||
| Nodes sampled | < .001 | .24 | ||||||||||
| Mean | 16.6 | 13.4 | 14.4 | 13.8 | 11.8 | |||||||
| Range | 3–49 | 0–59 | 3–59 | 1–51 | 0–47 | |||||||
| Stage III Patients: CALGB 89803 |
||||||||||||
| MMR Status |
18q Status |
|||||||||||
| Patients With MMR-D Tumors |
Patients With MMR-I Tumors |
Patients With 18q Intact |
Patients With 18qLOH Tumors |
Patients With Noninformative 18qLOH |
||||||||
| No. |
% |
No. |
% |
P |
No. |
% |
No. |
% |
No. |
% |
P |
|
| No. of patients | 131 | 779 | 79 | 445 | 78 | |||||||
| Treatment | .47 | .58 | ||||||||||
| FU/LV | 62 | 47.3 | 395 | 50.7 | 39 | 49.4 | 228 | 51.2 | 35 | 44.9 | ||
| IFL | 69 | 52.7 | 384 | 49.3 | 40 | 50.6 | 217 | 48.8 | 43 | 55.1 | ||
| Age, years | .52 | .025 | ||||||||||
| Mean | 61 | 60 | 59 | 60 | 63 | |||||||
| Range | 21–85 | 24–85 | 35–80 | 24–85 | 39–85 | |||||||
| Sex | .020 | .82 | ||||||||||
| Male | 59 | 45 | 436 | 56 | 45 | 57.0 | 251 | 56.4 | 47 | 57.0 | ||
| Female | 72 | 55 | 343 | 44 | 34 | 43.0 | 194 | 43.6 | 31 | 43.0 | ||
| Site of tumor | < .001 | .69 | ||||||||||
| Distal | 14 | 10.7 | 366 | 47 | 39 | 49.37 | 208 | 46.7 | 39 | 50.0 | ||
| Proximal | 115 | 87.8 | 403 | 51.7 | 37 | 46.84 | 235 | 52.8 | 38 | 48.7 | ||
| Unknown | 2 | 1.5 | 10 | 1.3 | 3 | 3.8 | 2 | 0.4 | 1 | 1.3 | ||
| Tumor differentiation | < .001 | .20 | ||||||||||
| Well | 2 | 1.5 | 48 | 6.2 | 0 | 26 | 5.8 | 6 | 7.8 | |||
| Moderate | 63 | 48.1 | 564 | 72.4 | 63 | 79.8 | 332 | 74.6 | 56 | 72.7 | ||
| Poor/undifferentiated | 64 | 48.9 | 159 | 20.4 | 13 | 16.5 | 86 | 19.3 | 15 | 19.5 | ||
| Unknown | 2 | 1.5 | 8 | 1 | 3 | 3.8 | 1 | 0.2 | 0 | |||
| Positive nodes | .95 | .28 | ||||||||||
| Mean | 3 | 3 | 4 | 3.4 | 3.5 | |||||||
| Range | 1–23 | 1–29 | 1–16 | 1–24 | 1–23 | |||||||
| Nodal ratio | .005 | .64 | ||||||||||
| Mean | 0.25 | 0.31 | 0.32 | 0.3 | 0.33 | |||||||
| SD | 0.21 | 0.25 | 0.26 | 0.24 | 0.27 | |||||||
| Nodes sampled | .007 | .32 | ||||||||||
| Mean | 16.7 | 14.3 | 13.9 | 14.0 | 12.4 | |||||||
| Range | 2–68 | 1–99 | 4–45 | 1–99 | 1–27 | |||||||
Abbreviations: 18qLOH, loss of heterozygosity at chromosomal location 18q; CALGB, Cancer and Leukemia Group B; FU/LV, fluorouracil plus leucovorin; IFL, fluorouracil, leucovorin, and irinotecan; MMR, mismatch repair; MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact; MoAb 17-1A, monoclonal antibody 17-1A; SD, standard deviation.